Reduction in:-IL-6, IL-1beta, TNF—α, and MCP-1 levels [97,98,99,100,101,102,103];-NADPH oxidase activity [104,105,106,107,108,109,110];-ROI’s production [104,105,106,107,108,109,110];-the infiltration of CD4+ T cells [104,105,106,107,108,109,110]; -IL-17 activity [112];-lymphocyte proliferation and IFN-gamma production in vitro assays, and suppressed antigen-specific Th1 and Th2 lymphocytes in vivo [115].No significant effect on:-IL-4, IL-13, and CRP levels in hypertensive patients [111];Increase in:-concentration of anti-inflammatory IL-10 [111]. The gene discussed is FMO5; the disease is hypertensive disorder.